Evaluation of biochemical and economic outcomes in patients treated with PCSK9 inhibitors in a real clinical practice setting
BACKGRO UND : PCSK9 inhibitors (PCSK9i) in combination with high-dose statins can reduce LDL -cholesterol (LDL-C) levels by 50-60% over statin monotherapy. This analysis investigated biochemical (LDL-C reduction) and economic outcomes in Italian patients treated with PCSK9i or potentially eligible but untreated.METHOD S: Administrative databases of healthcare institutions covering around 5 million residents were used… Read More »Evaluation of biochemical and economic outcomes in patients treated with PCSK9 inhibitors in a real clinical practice setting
Healthcare Costs and Treatment Patterns of Triplet Therapies in Relapsed/Refractory Multiple Myeloma: Real World Evidence from Italy
Purpose: This analysis sought to characterize patients with relapsed or refractory multiple myeloma (RRMM) on triplet therapy with immunomodulatory agents/proteasome inhibitors/monoclonal antibodies combined with dexamethasone, describing their demographic and clinical features, therapeutic pathways and the related healthcare costs for the Italian National Health Service (NHS).Patients and Methods: A retrospective observational analysis was conducted on administrative… Read More »Healthcare Costs and Treatment Patterns of Triplet Therapies in Relapsed/Refractory Multiple Myeloma: Real World Evidence from Italy
A Real-World Analysis of Patientswith Triple Class Exposed Multiple Myeloma in Italy: Epidemiology Estimates, Treatment Pattern and Economic Burden
ABSTRACTOBJECTIVES: This research aimed to provide updated epidemiological estimates of multiple myeloma (MM) in Italy andto characterize the clinical journey, treatment patterns, and economic burden focusing specifically on the subset of patientswho have been exposed to all three major therapeutic classes: proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies (triple-class exposed, TCE).METHODS: A retrospective analysis… Read More »A Real-World Analysis of Patientswith Triple Class Exposed Multiple Myeloma in Italy: Epidemiology Estimates, Treatment Pattern and Economic Burden
Evoluzione dei trattamenti per l’angioedema ereditarioin Italia: utilizzo del lanadelumab nella pratica clinica
Introduction: Hereditary angioedema (HEA) is a rare genetic disorder characterised by recurrent episodes ofedema affecting various body districts. HEA therapy includes treatment of acute attacks and short- or long-termprophylaxis.Objective: To describe the main demographic and clinical characteristics of patients with HEA in real Italian clinicalpractice, as well as the use of pharmacological treatments, the use… Read More »Evoluzione dei trattamenti per l’angioedema ereditarioin Italia: utilizzo del lanadelumab nella pratica clinica
Treatment Pathways, Drug Utilization and Healthcare Resource Consumption in Patients with Metastatic Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer: A Real-World Analysis with Administrative Databases in Italy
Background: Metastatic anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) is a rare but clinically distinct subtype of lung cancer with therapeutic sensitivity to ALK inhibitors (ALKi). Over the past decade, several ALKi have been introduced in Italy, yet real-world data on their utilization, patient characteristics, outcomes, and healthcare burden remain limited. Objectives: This… Read More »Treatment Pathways, Drug Utilization and Healthcare Resource Consumption in Patients with Metastatic Anaplastic Lymphoma Kinase-Positive Non-small Cell Lung Cancer: A Real-World Analysis with Administrative Databases in Italy
The role of sodium zirconium cyclosilicate drug utilization in managing hyperkalemia: impact on healthcare resource utilization and on maintenance of renin-angiotensin-aldosterone system inhibitor therapy in Italian clinical practice
Aims Hyperkalemia (HK) is prevalent in patients with chronic kidney disease (CKD) and heart failure, particularly those on renin-angiotensin-aldosterone system inhibitors (RAASi). However, HK treatment often necessitates RAASi discontinuation. Sodium zirconium cyclosilicate (SZC), reimbursed in Italy since 2021, offers a new treatment option for HK. This study aimed to assess real-world SZC use and resulting… Read More »The role of sodium zirconium cyclosilicate drug utilization in managing hyperkalemia: impact on healthcare resource utilization and on maintenance of renin-angiotensin-aldosterone system inhibitor therapy in Italian clinical practice
The Integrated Multidisciplinary Pathway for Large-Scale Management of Dyslipidemia in High-Risk Patients (ENNA) Project: Rationale and Project Design
Atherosclerotic cardiovasculardiseaseisaleadingcauseofmorbidityandmortalityglobally,significantlyinfluenced bymodifiable riskfactors,particularlyhypercholesterolemia.Despitetheavailabilityofeffectivelipid-reducing drugs,achievingthelow-densitylipoproteincholesterol(LDL-C)targetlevelsremainsasignif-icant challengeinclinicalpractice,contributingtopersistentlyhighratesofcardiovascularevents.TheintE-grated multidiscipliNarypathwayforlarge-scalemaNagementofdyslipidemiAinhigh-riskpatients(ENNA)Project wasdesignedtoaddressthealarmingratesofsuboptimallipidmanagementinpatientsathighandvery-high riskintheprovinceofEnna,Sicily.ThisprogramaimstooptimizeLDL-Ccontrolthroughaninte-grated caremodelthatfosterscollaborationamongpharmacists,generalpractitioners,andcardiologists,ulti-mately promotingapatient-centeredapproachtotherapy.Thepatientswhoareeligibleareidentified usingdata-driven methodsthroughprescriptionclaims,laboratoryresults,andhospitaldischargedata,facilitatedby localpharmacies.Generalpractitionersplayacrucialroleastheprimarycareprovidersforinitiatingoroptimizing lipid-reducingtherapy,whereascardiologistsareinvolvedinmanagingmorecomplexcasesrequiring specializedintervention.TheprimaryobjectiveoftheENNAProjectistoincreasethepercentageofpatients atgreatriskinwhomLDL-Ctargetsareachieved,improvingoveralllipidmanagementandthera-peutic adherence.
Differential Adherence to Free and Single‑Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real‑World Analysis in Italy
Abstract Introduction Adherence to cardiovascular drug treatment can significantly benefit from a reduced pill burden, but data on this matter derived from real-life settings are currently scanty. This analysis assessed the possible changes in adherence in patients treated with rosuvastatin and ezetimibe (ROS/EZE) as free multi-pill combination who switched to ROS/EZE as single-pill combination in… Read More »Differential Adherence to Free and Single‑Pill Combination of Rosuvastatin/Ezetimibe: Findings from a Real‑World Analysis in Italy
Un modello di Activity- Based Costing applicato al processo di gestione dei pazienti con emicrania presso l’IRCCS Fondazione Mondino
An Activity-Based Costing model applied to the management process of patients with migraine at IRCCSMondino FoundationBackground and aim: The ageing of the general population, with the increase in chronic diseases, poses theneed for using technological innovation to face the growing healthcare needs. The present analysis applied theActivity-Based Costing tool in migraine patients followed at the… Read More »Un modello di Activity- Based Costing applicato al processo di gestione dei pazienti con emicrania presso l’IRCCS Fondazione Mondino
Differenze di genere e ipercolesterolemia: evidenze real-world dallo studio WECARE (Women Effective CArdiovascular Risk Evaluation)
Gender differences and hypercholesterolemia: real-world evidence from the study WECARE (Women EffectiveCArdiovascular Risk Evaluation)Introduction: The therapeutic control of LDL-cholesterol is essential in cardiovascular prevention, as recommendedby the recent guidelines.Objective: To evaluate gender differences in terms of demographic and clinical characteristics, treatment pattern,treatment adherence and healthcare costs in patients on lipid-lowering therapy, stratified by cardiovascular riskin… Read More »Differenze di genere e ipercolesterolemia: evidenze real-world dallo studio WECARE (Women Effective CArdiovascular Risk Evaluation)